Diffuse Large B-cell LymphomaPhase 2DALY 2-EUNCT04844866
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
A Phase 2 study testing MB-CART2019.1 in people with Diffuse Large B-cell Lymphoma, run by Miltenyi Biomedicine GmbH at 51 sites in 14 countries.
Trial summary
In the current protocol version, there are two parts. Part I is a pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma, who are not eligible for… Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Diffuse Large B-cell Lymphoma
- What is being tested?
- MB-CART2019.1
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 213 participants
- Where
- 51 sitesin 14 countries
- Study dates
- 18 Aug 2021to 30 Sep 2031
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Part I:
- Histologically proven DLBCL and associated subtypes, according to the World Health Organization (WHO) 2016 classification including:
- DLBCL not otherwise specified (NOS).
- High-grade B-cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements with DLBCL/blastoid/intermediate histology or HGBL with MYC and BCL2 and/or BCL6 rearrangements (double hit lymphoma/triple hit lymphoma).
- High-grade BCL, NOS.
- Primary (thymic) large mediastinal BCL.
- Disease transformed from an earlier diagnosis of low-grade lymphoma (e.g. an indolent pathology such as follicular lymphoma, marginal zone lymphoma) into DLBCL with DLBCL disease progression subsequent to DLBCL-directed systemic treatment.
- Follicular lymphoma Grade 3B.
- Relapsed or refractory disease after first-line chemoimmunotherapy:
- Refractory disease defined as no CR to first-line therapy (e.g. R-CHOP [rituximab, cyclophosphamide, daunorubicin, vincristine and prednisone]).
- Progressive disease (PD) after at least 2 full cycles of first-line therapy.
- Stable disease (SD) after 4 cycles of first-line therapy.
- PR as best response after at least 6 cycles of first-line therapy and biopsy-proven persistent disease (except where prohibited due to comorbidities) within ≤ 24 months from the start of the first-line therapy.
- Relapsed disease defined as complete remission to first-line therapy followed by biopsy-proven disease progression (except where prohibited due to comorbidities) within ≤ 24 months from the start of the first-line therapy.
- Participants must have received adequate first-line therapy containing at least the combination of an anthracycline-based regimen and rituximab (anti-CD20 monoclonal antibody). Local therapies (e.g. radiotherapies) will not be considered as line of therapy if performed during the same line of treatment.
- Archival paraffin-embedded tumour tissue acquired ≤ 2 years (preferred: ≤ 2 months) prior to screening for the central pathology review to confirm DLBCL diagnosis must be made available for participation in this study. If archival paraffin-embedded tumour tissue is not available, fresh tumour tissue sample (preferred) or core-needle biopsy must be made available for the central pathology review.
- Participants deemed ineligible to receive HDC followed by ASCT based on the treating physician's assessment and meeting the following criteria: EITHER
- Age ≥ 18 years and
- Prior ASCT (as first-line consolidation) or
- Haematopoietic cell transplantation-specific comorbidity index (HCT-CI) > 3. OR
- Age ≥ 65 years and ≥ 1of the criteria below:
- Impaired cardiac function (left ventricular ejection fraction [LVEF] < 50%), or
- Impaired renal function (estimated glomerular filtration rate [eGFR] < 60 mL/min) calculated according to the modified Modification of Diet in Renal Disease (MDRD) formula, or
- Impaired pulmonary function (diffusing capacity for carbon monoxide or forced expiratory volume in 1 second < 80%) or dyspnoea on slight activity, or
- Eastern Cooperative Oncology Group (ECOG) performance status > 1. OR
- Age ≥ 70 years. Documentation of the reason for ineligibility for ASCT must be present in the participant's source data. In addition, all participants must fulfil the following criteria:
- Age ≥ 18 years.
- Measurable disease according to Lugano criteria. The lesion must be measurable (nodes > 1.5 cm in the long axis; extranodal lesions > 1 cm in the long axis) and positive on a positron emission tomography scan.
- Estimated life expectancy of > 3 months for other reasons than the primary disease.
- Women of childbearing potential (WOCBP) must agree to use highly effective contraceptive measures (Pearl index < 1) or practice true sexual abstinence from any heterosexual intercourse (True abstinence is only acceptable if it is in line with the preferred and usual life style of the participant.) or must have a vasectomised partner as the sole sexual partner (The vasectomised partner must have received medical assessment of the surgical success.) for at least 1 month before the study start, during the study and in the 12 months following the last dose of study treatment. A woman is considered a WOCBP, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Highly effective methods of contraception include hormonal contraceptives associated with inhibition of ovulation (oral, intravaginal, transdermal, injectable, implantable) and intrauterine devices or systems (e.g. hormonal and non-hormonal) and bilateral tubal occlusion. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A post-menopausal state is defined as no menses for 12 months without an alternative medical cause. WOCBP who want to become pregnant after completing treatment should seek advice about oocyte cryoconservation prior to treatment because of possible irreversible infertility. WOCBP must refrain from egg donation throughout the study until 12 months after the last dose of study treatment. Men with non-pregnant WOCBP partners must agree to use highly effective contraceptive measures (Pearl index < 1, e.g. spermicide and condom or other highly effective contraceptive measures (Pearl index < 1) taken by their WOCBP partner) or practice true sexual abstinence from any heterosexual intercourse (True abstinence is only acceptable if it is in line with the preferred and usual life style of the participant.), unless they are surgically sterile (meaning at least 2 consecutive analyses following vasectomy demonstrate absence of sperms in the ejaculate), during the study and in the 12 months following the last dose of study treatment. Men should seek advice about sperm conservation prior to treatment because of possible irreversible infertility. Men must furthermore refrain from sperm donation throughout the study until 12 months after the last administration of study treatment.
- In the opinion of the investigator, the participant must be able to comply with all study-related procedures, medication use and evaluations.
- Mental capacity and legal ability to consent to participation in the clinical study.
Criteria for Exclusion:
- Contraindications for R-GemOx, BR plus polatuzumab vedotin, cyclophosphamide and fludarabine as judged by the treating physician.
- Prior chimeric antigen receptor therapy or other genetically modified T-cell therapy.
- Participants who have received more than one line of treatment for DLBCL or associated subtypes.
- Prior haematopoietic stem cell transplantation (HSCT; as first-line consolidation) < 3 months at the time of leukapheresis.
- ECOG performance status > 2.
- Absolute neutrophil count < 1,000/μL (unless secondary to bone marrow involvement by DLBCL as demonstrated by bone marrow biopsy).
- Platelet count < 50,000/μL (unless secondary to bone marrow involvement by DLBCL as demonstrated by bone marrow biopsy).
- Absolute lymphocyte count < 100/μL.
- Participants who have central nervous system (CNS) lymphoma involvement in present or past medical history.
- Participants with the requirement for urgent therapy due to tumour mass effects.
- Infection with human immunodeficiency virus.
- Presence of active or prior hepatitis B or C as indicated by serology (for detailed criteria see Section 10.2.7.10). Treated infection with hepatitis B or C virus unless confirmed to be polymerase chain reaction negative.
- Active infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Active, severe systemic fungal, viral or bacterial infection.
- Known history or evidence of severely immunocompromised state, i.e. corticosteroid treatment > 10 mg/day for more than 6 months.
- Has received vaccination with live virus vaccines 6 weeks prior to randomisation.
- Prior CD19-targeted therapy.
- Known history or presence of seizure activities or on active anti-seizure medications within the previous 12 months.
- History or presence of non-malignant CNS disease that, in the judgement of the investigator, may impair the ability to evaluate neurotoxicity.
- Known history or presence of autoimmune CNS disease, such as multiple sclerosis, optic neuritis or other immunologic or inflammatory disease.
- Known history or presence of cerebral vascular accident (CVA) within 12 months prior to randomisation. Note: In case of history of CVA > 12 months prior to leukapheresis, then the participant must not have any unstable or life-threatening neurological deficits.
- Participants with Richter's transformation or Richter's syndrome.
- Participants who are concurrently on any other experimental treatments or during the previous 4 weeks or 5 half-lives.
- Clinical heart failure with New York Heart Association class ≥ 2 or LVEF < 30% or severe cardiac arrhythmias or QT prolongation (resting QTcF ≥ 450 msec [male] or ≥ 460 msec [female] at screening) that would (according to the evaluation of the investigator) face an uncontrollable risk by receiving the medications administered in the trial.
- Resting peripheral oxygen saturation < 90% on room air.
- Liver dysfunction as indicated by total bilirubin > 2.5 × institutional upper limit of normal (ULN), aspartate aminotransferase and/or alanine aminotransferase > 5 × ULN or typical symptoms like jaundice.
- Serum creatinine ≥ 2.0 × ULN or eGFR < 30 mL/min calculated according to the modified MDRD formula.
- Pregnant or breast-feeding women.
- Prior history of malignancies other than DLBCL. Exceptions include participants who have been free of the disease for ≥ 3 years prior to screening and participants with adequately treated and removed basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, carcinoma in situ of the bladder or incidental histological finding of untreated localised (T1a, T1b or T1c) prostate cancer under surveillance.
- History of severe immediate hypersensitivity to any investigational medicinal product (IMP), auxiliary medicinal product (AxMP), premedication or rescue medication or its excipients that is scheduled to be given during study participation.
- Major surgery less than 30 days before start of treatment.
- Any medical condition likely to interfere with assessment of safety or efficacy of study treatment.
Part II:
- Histologically proven DLBCL and associated subtypes, according to the WHO 2016 classification including:
- DLBCL, NOS.
- HGBL with MYC and BCL2 and/or BCL6 rearrangements with DLBCL/blastoid/intermediate histology or HGBL with MYC and BCL2 and/or BCL6 rearrangements (double hit lymphoma/triple hit lymphoma).
- High-grade BCL, NOS.
- Primary (thymic) large mediastinal BCL.
- Disease transformed from an earlier diagnosis of low-grade lymphoma (e.g., an indolent pathology such as follicular lymphoma, marginal zone lymphoma) into DLBCL with DLBCL disease progression subsequent to DLBCL-directed systemic treatment.
- Follicular lymphoma Grade 3B.
- Relapsed or refractory disease after first-line chemoimmunotherapy:
- Refractory disease defined as no CR to first-line therapy (e.g., R-CHOP).
- PD after at least 2 full cycles of first-line therapy.
- SD after 4 cycles of first-line therapy.
- PR as best response after at least 6 cycles of first-line therapy and biopsy-proven persistent disease (except where prohibited due to comorbidities) within ≤ 12 months after completion of first-line treatment.
- Relapsed disease defined as complete remission to first-line therapy followed by biopsy-proven disease progression (except where prohibited due to comorbidities) within ≤ 12 months after completion of first-line treatment.
- Participant must have received adequate first-line therapy containing at least the combination of an anthracycline-based regimen and rituximab (anti-CD20 monoclonal antibody). Local therapies (e.g., radiotherapies) will not be considered as line of therapy if performed during the same line of treatment.
- Archival paraffin-embedded tumour tissue acquired ≤ 2 years (preferred: ≤ 2 months) prior to screening for the central pathology review to confirm DLBCL diagnosis must be made available for participation in this study. If archival paraffin-embedded tumour tissue is not available, fresh tumour tissue sample (preferred) or core-needle biopsy must be made available for the central pathology review.
- Measurable disease according to Lugano criteria. The lesion must be measurable (nodes > 1.5 cm in the long axis; extranodal lesions > 1 cm in the long axis) and positive on a positron emission tomography scan.
- Approved treatment options not suitable according to investigator's assessment. In addition, all participants must fulfil the following criteria:
- Age ≥ 18 and ≤ 70 years.
- Estimated life expectancy of > 3 months for other reasons than the primary disease.
- ECOG 0-1.
- Adequate bone marrow function, defined as:
- Absolute neutrophil count ≥ 1,000/μL (unless secondary to bone marrow involvement by DLBCL as demonstrated by bone marrow biopsy).
- Platelet count ≥ 50,000/μL (unless secondary to bone marrow involvement by DLBCL as demonstrated by bone marrow biopsy).
- Absolute lymphocyte count ≥ 100/μL.
- Adequate organ function, defined as:
- New York Heart Association class < 2 or LVEF ≥ 50%.
- No severe cardiac arrhythmias or QT prolongation (resting QTcF < 450 msec [male] or < 460 msec [female] at screening).
- No clinically relevant pleural effusion or pericardial effusion.
- Resting peripheral oxygen saturation ≥ 92% on room air.
- Total bilirubin ≤ 2.0 × ULN, AST and/or ALT ≤ 5 × ULN
- Serum creatinine < 1.0 × ULN or eGFR (according to modified MDRD formula) ≥ 60 mL/min.
- WOCBP must agree to use highly effective contraceptive measures (Pearl index < 1) or practice true sexual abstinence from any heterosexual intercourse (True abstinence is only acceptable if it is in line with the preferred and usual life style of the participant.) or must have a vasectomised partner as the sole sexual partner (The vasectomised partner must have received medical assessment of the surgical success.) for at least 1 month before the study start, during the study and in the 12 months following the last dose of study treatment. A woman is considered a WOCBP, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Highly effective methods of contraception include hormonal contraceptives associated with inhibition of ovulation (oral, intravaginal, transdermal, injectable, implantable) and intrauterine devices or systems (e.g., hormonal and non-hormonal) and bilateral tubal occlusion. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A post-menopausal state is defined as no menses for 12 months without an alternative medical cause. WOCBP who want to become pregnant after completing treatment should seek advice about oocyte cryoconservation prior to treatment because of possible irreversible infertility. WOCBP must refrain from egg donation throughout the study until 12 months after the last dose of study treatment. Men with non-pregnant WOCBP partners must agree to use highly effective contraceptive measures (Pearl index < 1, e.g., spermicide and condom or other highly effective contraceptive measures (Pearl index < 1) taken by their WOCBP partner) or practice true sexual abstinence from any heterosexual intercourse (True abstinence is only acceptable if it is in line with the preferred and usual life style of the participant.), unless they are surgically sterile (meaning at least 2 consecutive analyses following vasectomy demonstrate absence of sperms in the ejaculate), during the study and in the 12 months following the last dose of study treatment. Men should seek advice about sperm conservation prior to treatment because of possible irreversible infertility. Men must furthermore refrain from sperm donation throughout the study until 12 months after the last administration of study treatment.
- In the opinion of the investigator, the participant must be able to comply with all study-related procedures, medication use and evaluations.
- Mental capacity and legal ability to consent to participation in the clinical study.
Criteria for Exclusion:
- Contraindications for cyclophosphamide and fludarabine as judged by the treating physician.
- Prior chimeric antigen receptor therapy or other genetically modified T-cell therapy.
- Participants who have received more than one line of prior therapy for DLBCL or associated subtypes.
- Prior HSCT (as first-line consolidation) < 3 months at the time of leukapheresis.
- Participants who have CNS lymphoma involvement in present or past medical history.
- Participants with the requirement for urgent therapy due to tumour mass effects.
- Infection with human immunodeficiency virus.
- Presence of active or prior hepatitis B or C as indicated by serology. Treated infection with hepatitis B or C virus unless confirmed to be polymerase chain reaction negative.
- Infection with Treponema pallidum (pathogen causing syphilis).
- Infection with human T-lymphotropic virus 1.
- Active infection with SARS-CoV-2.
- Active, severe systemic fungal, viral, or bacterial infection.
- Known history or evidence of severely immunocompromised state, i.e. corticosteroid treatment > 10 mg/day for more than 6 months.
- Has received vaccination with live virus vaccines within 6 weeks prior to randomisation.
- Prior CD19-targeted therapy.
- Known history or presence of seizure activities or on active anti-seizure medications within the previous 12 months.
- History or presence of non-malignant CNS disease that, in the judgement of the investigator, may impair the ability to evaluate neurotoxicity.
- Known history or presence of autoimmune CNS disease, such as multiple sclerosis, optic neuritis or other immunologic or inflammatory disease.
- Known history or presence of CVA within 12 months prior to randomisation. Note: In case of history of CVA > 12 months prior to leukapheresis, then the participant must not have any unstable or life-threatening neurological deficits.
- Participants with Richter's transformation or Richter's syndrome.
- Participants who are concurrently on any other experimental treatments or during the previous 4 weeks or 5 half-lives.
- Pregnant or breastfeeding woman.
- Prior history of malignancies other than DLBCL. Exceptions include participants who have been free of the disease for ≥ 3 years prior to screening and participants with adequately treated and removed basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, carcinoma in situ of the bladder or incidental histological finding of untreated localised (T1a, T1b or T1c) prostate cancer under surveillance.
- History of severe immediate hypersensitivity to any IMP, AxMP, premedication or rescue medication or its excipients that is scheduled to be given during study participation.
- Major surgery less than 30 days before start of treatment.
- Any medical condition likely to interfere with assessment of safety or efficacy of study treatment.
Trial locations and contacts
51 sites in 14 countries. Contact the study team or a site near you to ask about taking part.
51 sites in 14 countries
Germany11 sites, 11 recruiting
- Recruiting
Universitatsklinikum Augsburg
Augsburg, 86156
Christoph Schmid, Dr., +49 821 4003714, christoph.schmid@klinikum-augsburg.de
- Recruiting
Universitaetsklinikum Knappschaftskrankenhaus Bochum der Ruhr-Universitat Bochum
Bochum, 44892
Roland Schroers, Prof., +49 2342993447, roland.schroers@rub.de
- Recruiting
Universitaetsklinikum Koeln
Cologne, 50937
Peter Borchmann, Prof., +49 221 478 88159, peter.borchmann@uk-koeln.de
- Recruiting
Klinikum Erlangen der Friedrich-Alexander-Universitaet Erlangen-Nuernberg
Erlangen, 91054
Andreas Mackensen, Prof. Dr., +49 9131 85-35954, andreas.mackensen@uk-erlangen.de
- Recruiting
Universitaetsklinikum Essen
Essen, 45147
Bastian Von Tresckow, Dr., +49 2017233136, bastian.vontresckow@uk-essen.de
- Recruiting
University Medical Center Hamburg-Eppendorf
Hamburg, 20246
Francis Ayuk, Prof. Dr., +49 40741054850, ayuketan@uke.de
- Recruiting
Universitaetsklinikum Heidelberg
Heidelberg, 69120
Peter Dreger, Prof. Dr., +49 6221568008, peter.dreger@med.uni-heidelberg.de
- Recruiting
Universitätsklinikum Leipzig
Leipzig, 04103
Vladan Vucinic, Dr. med., +49 341 97 13050, Vladan.Vucinic@medizin.uni-leipzig.de
- Recruiting
Klinikum der Universitat München, Studienzentrale fur Hematologie der Medizinischen Klinik II
München, 81377
Veit Bücklein, Dr., +49 8944000, veit.buecklein@med.uni-muenchen.de
- Recruiting
University Hospital Regensburg
Regensburg, 93053
Matthias Edinger, Prof. Dr., +49 94 9445580, matthias.edinger@ukr.de
- Recruiting
University Hospital of Tuebingen
Tübingen, 72076
Wolfgang Bethge, Prof. Dr., +49 70712983176, wolfgang.bethge@med.uni-tuebingen.de
France9 sites, 5 recruiting
- Recruiting
Centre Hospitalier Universitaire (CHU) - Hopital Henri Mondor
Créteil, 94010
Francois Lemmonier, Dr., +33 1 49 81 21 71, Francois.LeMonnier@aphp.fr
- Active, not recruiting
CHRU de Lille - Hopital Claude Huriez
Lille, 59000
- Active, not recruiting
Centre Hospitalier Lyon Sud, Hospices Civils de Lyon Groupement Hospitalier Sud
Lyon, 69495
- Active, not recruiting
Centre Paoli Calmettes
Marseille, 13273
- Active, not recruiting
Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hopital Hotel Dieu
Nantes, 44093
- Recruiting
Centre Hospitalier Universitaire de Bordeaux - Hopital Haut-Leveque
Pessac, 33600
Francois-Xavier Gros, Dr., +33 5 57 65 64 94, francois-xavier.gros@chu-bordeaux.fr
- Recruiting
Centre Hospitalier Universitaire de Poitiers
Poitiers, 86000
Stephanie Guidez, Dr., +33 5 49 44 46 89, stephanie.guidez@chu-poitiers.fr
- Recruiting
Institut Universitaire du Cancer Service d´hématologie
Toulouse, 31059
Pierre Bories, Dr., +33 531 1565 14, bories@onco-occitanie.fr
- Recruiting
CHU de Nancy Hopitaux de Brabois
Vandœuvre-lès-Nancy, 54500
Pierre Feugier, Prof., +33 383153282, p.feugier@chru-nancy.fr
Spain7 sites, 7 recruiting
- Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, 08035
Gloria Iacoboni Garcia-Calvo, Dr., +34 680522422, giacoboni@vhio.net
- Recruiting
Hospital Clinic de Barcelona (Hospital Clinic i Provincial)
Barcelona, 08036
Ana Triguero, Dr., +34 93 227 43 53 ext. 4366, atriguero@clinic.cat
- Recruiting
Catalan Institute of Oncology (ICO) Hospitalet
Barcelona, 08907
Anna Sureda Balari, Dr., +34 935565649, asureda@iconcologia.net
- Recruiting
Hospital Clínico San Carlos (HCSC)
Madrid, 28040
Daniel Morillo Giles, Dr., dmorillo@startmadrid.com
- Recruiting
Hospital Universitario Virgen De La Arrixaca (Huva)
Murcia, 30120
Antonio Salar Silvestre, Dr., +34 932483343, antonio.salar2@carm.es
- Recruiting
Clinica Universidad de Navarra
Pamplona, 31008
Carlos Grande Garcia, Dr., +34 913 531 920, cgrandeg@unav.es
- Recruiting
Hospital Clinico Universitario de Salamanca
Salamanca, 37007
Alejandro Martin Garcia-Sancho, Dr., +34 923291384, amartingar@usal.es
Austria4 sites, 3 recruiting
- Active, not recruiting
LKH - Medizinische Universitaet Graz
Graz, 8036
- Recruiting
Universitatsklinikum Innsbruck Universitatsklinik fur Innere Medizin V
Innsbruck, 6020
Norman Steiner, Dr., normann.steiner@tirol-kliniken.at
- Recruiting
Ordensklinikum Linz GmbH Elisabethinen
Linz, 4020
Veronika Buxhofer-Ausch, Dr., +4373276764409, veronika.buxhofer@elisabethinen.or.at
- Recruiting
Medizinische Universitaet Wien - Allgemeines Krankenhaus der Stadt Wien (AKH)
Vienna, 1090
Ulrich Jaeger, Prof., +4314040044090, ulrich.jaeger@meduniwien.ac.at
Netherlands4 sites, 3 recruiting
- Recruiting
Amsterdam Universitaire Medische Centra (UMC) - locatie Amsterdam Medisch Centrum (AMC)
Amsterdam, 1105 AZ
Marie Kersten, Dr., +31 20566 5955, m.j.kersten@amsterdamumc.nl
- Recruiting
University Medical Center Groningen
Groningen, 9713 GZ
Tom van Meerten, Dr., +31 503616161, t.van.meerten@umcg.nl
- Recruiting
Leiden University Medical Center (LUMC)
Leiden, 2333 ZA
Aniko Sijs Szabo, Dr., +31 71 5296524, a.sijs-szabo@lumc.nl
- Active, not recruiting
Erasmus University Medical Center
Rotterdam, 3015 GC
Finland3 sites, 3 recruiting
- Not yet recruiting
Helsinki University Comprehensive Cancer Center
Helsinki, 00029
Sirpa Leppa, Prof., +358 5042 70820, sirpa.leppa@hus.fi
- Recruiting
Oulu University Central Hospital
Oulu, 90220
Hanne Kuitunen, Dr., hanne.kuitunen@ppshp.fi
- Recruiting
Turku University Hospital
Turku, 20520
Juha Ranti, Dr, juha.ranti@varha.fi
Turkey (Türkiye)3 sites, 3 recruiting
- Not yet recruiting
Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Ankara, 06200
Fevzi Altuntas, Prof. Dr., +90 532 658 80 50, fevzi.altuntas1@saglik.go.tr
- Not yet recruiting
American Hospital
Şişli, 34365
Burhan Ferhanoglu, Prof. Dr., +90 2122 335336, burhanf@amerikanhastanesi.org
- Not yet recruiting
Koc Universitesi Hastanesi (Koc University Hospital)
Zeytinburnu, 34010
Sinem Civriz Bozdag, Prof., +90 5057 658142, sbozdag@kuh.ku.edu.tr
Belgium2 sites, 2 recruiting
- Recruiting
Jules Bordet lnstitute
Anderlecht, 1070
Fulvio Massaro, Dr., fulvio.massaro@hubruxelles.be
- Recruiting
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
Leuven, 3000
Peter Vandenberghe, Prof., +32 16346889, peter.vandenberghe@uzleuven.be
Czechia2 sites, 2 recruiting
- Recruiting
University Hospital Hradec Kralove
Hradec Králové, 50005
David Belada, Dr., +420 602128826, david.belada@seznam.cz
- Recruiting
FNsP Ostrava
Ostrava, 70852
Michal Kascak, Dr., +420 597 371 111, michal.kascak@fno.cz
Hungary2 sites, 2 recruiting
- Recruiting
Del-Pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet
Budapest, 1097
Laszlo Gopcsa, Dr., gopcsa.laszlo@dpckorhaz.hu
- Recruiting
Debreceni Egyetem - Orvos es Egeszsegtudomanyi Centrum (DEOEC) (University of Debrecen Medical and Health Science Center)
Debrecen, 4032
Arpad Illes, Prof. Dr., +36 52255601, illesarpaddr@gmail.com
Croatia1 site, 1 recruiting
- Recruiting
University Hospital Center Zagreb
Zagreb, 10000
Igor Aurer, Prof., +385 1238 8265, iaurer@kbc-zagreb.hr
Italy1 site, 1 recruiting
- Recruiting
Azienda Ospedaliera San Giovanni Battista Di Torino
Torino, 10126
Barbara Botto, Dr., +39 116335967, bbotto@cittadellasalute.to.it
Poland1 site
- Active, not recruiting
Uniwersytecki Szpital Kliniczny - Klinika Hematologii, Terapii Komorkowych i Chorob Wewnetrznych
Wroclaw, 50367
Portugal1 site, 1 recruiting
- Not yet recruiting
Instituto Portugues de Oncologia do Porto Francisco Gentil E.P.E
Porto, 4200-072
Jose Mario Mariz, Dr., +351 2250 84000, mariz@ipoporto.min-saude.pt
About this study
Official title: A Pivotal Phase II Randomised, Multi-centre, Open-label Study to Evaluate the Efficacy and Safety of MB-CART2019.1 Compared to SoC Therapy in Participants With r/r DLBCL, Who Are Not Eligible for HDC and ASCT
In the current protocol version, there are two parts. Part I is a pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma, who are not eligible for high-dose chemotherapy and autologous stem cell transplantation.
Part II is a Phase II single-arm, open-label, multi-centre study evaluating the efficacy and safety of MB-CART2019.1 in younger, fit participants with R-R DLBCL. Part II will start after completion of enrolment in Part I.
Read the detailed description
In Part I, the study should determine superiority of MB-CART2019.1 treatment compared to SoC therapy with R-GemOx (rituximab, gemcitabine and oxaliplatin) with respect to event-free survival in second-line therapy in participants with R-R DLBCL, who are non-eligible for high-dose chemotherapy and autologous stem cell transplantation.
MB-CART2019.1 is designed to effectively target malignant B cells in patients suffering from late stage haematological B-cell malignancies. MB-CART2019.1 consists of autologous cluster of differentiation CD20/CD19 chimeric antigen receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis and processed by using the CliniMACS Prodigy®. Patients who are suitable for this study will be randomized 1:1 to either MB-CART2019.1 or SoC. Both treatment arms are unblinded.
MB-CART2019.1 arm: Single infusion of fresh formulation of 2.5 × 10^6 CAR-transduced autologous T cells. IMP is only to be administered after a lymphodepleting chemotherapy with fludarabine and cyclophosphamide. For MB-CART2019.1 production, patients will undergo a leukapheresis.
SoC arm: R-GemOx (8 cycles of 14 days each) or (10% of SoC arm) BR (Bendamustine/Rituximab) + polatuzumab vedotin (6 cycles of 21 days each). Participants from the SoC arm are allowed to be treated with MB-CART2019.1 upon request by the investigator if at least one of the following criteria is confirmed by the IRC:
- Relapse or progression occurring at any time within 1 year after randomisation.
- Failure to achieve PR or CR at or beyond Week 8 after randomisation (after 4 cycles of R-GemOx or 3 cycles of BR plus polatuzumab vedotin) and the start of a new anti-lymphoma therapy is warranted.
The duration of the active part of the study for each individual participant from screening to the end of the 1-year follow-up after infusion of MB-CART2019.1 cells (experimental arm) or the start of SoC therapy (comparator arm) will be approximately 55 weeks. The LTFU in Year 2 after infusion of MB-CART2019.1 cells or the start of treatment in the comparator arm will not be part of the active part of the clinical study and will be reported separately.
In Part II, the study should evaluate the efficacy of MB-CART2019.1 in younger, fit participants with R-R DLBCL. Approximately 45 participants will be enrolled in this part to obtain 40 evaluable participants for the analysis of the primary endpoint.
Screening will take place within 4 weeks before leukapheresis. In individual cases, the sponsor may agree to extending the screening period by up to two weeks. Only participants satisfying all protocol inclusion and none of the exclusion criteria will be included in the clinical study.
- Conditions
- Diffuse Large B-cell Lymphoma
- Being tested
- MB-CART2019.1, Standard of Care
- Keywords
- CAR T cells, chimeric antigen receptor, MB-CART2019.1, CD20, CD19, relapsed refractory, Diffuse Large B-cell Lymphoma, DLBCL, Non-Hodgkin Lymphoma, NHL, zamtocabtagene autoleucel, blood cancer, LBCL, Follicular Lymphoma 3B
- Medical subject headings
- Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Hematologic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MB-CART2019.1Genetic
Also called Zamtocabtagene Autoleucel, Zamto-cel
MB-CART2019.1 is designed to effectively target malignant B cells in patients suffering from late stage haematological B-cell malignancies. MB-CART2019.1 consists of autologous cluster of differentiation CD20/CD19 chimeric antigen receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis and processed by using the CliniMACS Prodigy® device.
Standard of CareDrug
Also called Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Standard of Care
| Study group | Role | What they receive |
|---|---|---|
| Part I: CAR T-cell MB-CART2019.1 | Experimental | Single infusion of 2.5 × 10^6 CAR-transduced autologous T cells per kg/body weight. Receives: Genetic: MB-CART2019.1 |
| Part II: CAR T-cell MB-CART2019.1 | Experimental | Single infusion of 2.5 × 10^6 CAR-transduced autologous T cells per kg/body weight. Receives: Genetic: MB-CART2019.1 |
| PART I: Standard of Care | Active comparator | R-GemOx R-Pola Receives: Drug: Standard of Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Part I: Event-free survival
Event-free survival (EFS), defined as the time between the date of randomisation and the date of objective disease progression, failure to achieve partial response (PR) or complete response (CR) at or beyond Week 8 after randomisation leading to a new anti-lymphoma therapy or death of any cause, whichever occurs first, based on independent review committee (IRC) assessment.
Measured: up to 30 weeks after randomisation
Part II: Best objective response rate
Best objective response rate (BORR), defined as the proportion of participants with at least one CR or PR between the date of MB-CART2019.1 infusion and the date of objective disease progression, the start of new anti-lymphoma therapy or the date of death from any cause, whichever occurs first, based on IRC assessment.
Measured: up to 30 weeks after administration of MB-CART2019.1
Secondary outcomes (9)
Part I: Progression-free survival (PFS)
defined as the time between the date of randomisation and the date of objective disease progression or death of any cause, whichever occurs first, based on IRC assessment.
Measured: up to 99 weeks after randomisation
Part I: Best complete response rate
To evaluate the safety and toxicity of MB-CART2019.1 compared to SoC therapy.
Measured: up to 99 weeks after randomisation
Part I: Duration of complete response
To evaluate the safety and toxicity of MB-CART2019.1 compared to SoC therapy.
Measured: up to 91 weeks
Part I: Overall Survival
To evaluate the safety and toxicity of MB-CART2019.1 compared to SoC therapy.
Measured: up to 99 weeks after randomisation
Part II: Duration of Response (DOR)
defined as the time between the date of a first objective response (CR/PR) after MB-CART2019.1 infusion and the date of assessment of objective disease progression or the date of death
Measured: up to 91 weeks
Part II: Progression-free survival (PFS)
defined as the time between the date of leukapheresis and the date of objective disease progression or death
Measured: up to 99 weeks after leukapheresis
Part II: Overall Survival (OS)
defined as time between the date of leukapheresis and the date of death
Measured: up to 99 weeks after leukapheresis
Part II: Best Complete Response Rate (BCRR)
defined as the proportion of participants with CR between the date of MB-CART2019.1 infusion and the date of objective disease progression, the start of new anti-lymphoma therapy or the date of death
Measured: up to 99 weeks after leukapheresis
Part II: Duration of Complete Response (DOCR)
defined as the time between the date of a first CR and the date of assessment of objective disease progression or the date of death
Measured: up to 91 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Apr 2021
- Study start18 Aug 2021
- Primary completion15 Jan 2025
- Study completion30 Sep 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Diffuse Large B-cell LymphomaStudies of the same condition, open and under way.
- More trials run by Miltenyi Biomedicine GmbHThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Model description
- Recruitment completed in Part I: unblinded 1:1 randomization into IMP or SoC (168 patients) Recruitment ongoing in Part II: unblinded, single arm, non-randomized, IMP only (approx. 45 patients)
- Masking
- None (open label)
- Enrolment
- 213 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Miltenyi Biomedicine GmbH
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- ICON plc
- Responsible party
- Sponsor
- Investigators
- Peter Borchmann, Prof. Dr., Principal investigator, University Hospital of Cologne
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04844866
- Sponsor's protocol ID
- M-2020-371
- Acronym
- DALY 2-EU
- Status last verified
- Dec 2025
- First submitted
- 30 Mar 2021
- Last updated
- 10 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Borchmann P, van Meerten T, Iacoboni G, Bories P, Dreger P, Mutsaers P, Gopcsa L, Edinger M, Gergely L, von Tresckow B, Neumeister P, Steiner N, Jager U, Moreno AT, Griskevicius L, Lemonnier F, van Doesum J, Kersten MJ, Rudzki JD, Shah NN, Orentas R, Friedrichs B, Miltenyi S, Overstijns T, Burger I, Zadoyan G, Brillant C, Paul P, van Heteren P, Holtkamp S, Vandenberghe P. Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study. Lancet Oncol. 2026 Nov;27(11):1403-1419. doi: 10.1016/S1470-2045(26)00290-1.
PubMed 42933440
Study at a glance
From the registry record, last updated by the sponsor on 10 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Pivotal Phase II Randomised, Multi-centre, Open-label Study to Evaluate the Efficacy and Safety of MB-CART2019.1 Compared to SoC Therapy in Participants With r/r DLBCL, Who Are Not Eligible for HDC and ASCT
- ClinicalTrials.gov ID
- NCT04844866
- Acronym / sponsor ID
- DALY 2-EU / M-2020-371
- Conditions
- Diffuse Large B-cell Lymphoma
- Keywords
- CAR T cells, chimeric antigen receptor, MB-CART2019.1, CD20, CD19, relapsed refractory, Diffuse Large B-cell Lymphoma, DLBCL
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 213 participants (estimated)
- Lead sponsor
- Miltenyi Biomedicine GmbHIndustry (pharma, biotech, devices)
- Collaborators
- ICON plc
- Study start
- 18 Aug 2021 (actual)
- Primary completion
- 15 Jan 2025 (actual)
- Study completion
- 30 Sep 2031 (estimated)
- First posted
- 14 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In the current protocol version, there are two parts. Part I is a pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma, who are not eligible for high-dose chemotherapy and autologous stem cell transplantation.
Part II is a Phase II single-arm, open-label, multi-centre study evaluating the efficacy and safety of MB-CART2019.1 in younger, fit participants with R-R DLBCL. Part II will start after completion of enrolment in Part I.
Detailed description
In Part I, the study should determine superiority of MB-CART2019.1 treatment compared to SoC therapy with R-GemOx (rituximab, gemcitabine and oxaliplatin) with respect to event-free survival in second-line therapy in participants with R-R DLBCL, who are non-eligible for high-dose chemotherapy and autologous stem cell transplantation.
MB-CART2019.1 is designed to effectively target malignant B cells in patients suffering from late stage haematological B-cell malignancies. MB-CART2019.1 consists of autologous cluster of differentiation CD20/CD19 chimeric antigen receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis and processed by using the CliniMACS Prodigy®. Patients who are suitable for this study will be randomized 1:1 to either MB-CART2019.1 or SoC. Both treatment arms are unblinded.
MB-CART2019.1 arm: Single infusion of fresh formulation of 2.5 × 10^6 CAR-transduced autologous T cells. IMP is only to be administered after a lymphodepleting chemotherapy with fludarabine and cyclophosphamide. For MB-CART2019.1 production, patients will undergo a leukapheresis.
SoC arm: R-GemOx (8 cycles of 14 days each) or (10% of SoC arm) BR (Bendamustine/Rituximab) + polatuzumab vedotin (6 cycles of 21 days each). Participants from the SoC arm are allowed to be treated with MB-CART2019.1 upon request by the investigator if at least one of the following criteria is confirmed by the IRC:
- Relapse or progression occurring at any time within 1 year after randomisation.
- Failure to achieve PR or CR at or beyond Week 8 after randomisation (after 4 cycles of R-GemOx or 3 cycles of BR plus polatuzumab vedotin) and the start of a new anti-lymphoma therapy is warranted.
The duration of the active part of the study for each individual participant from screening to the end of the 1-year follow-up after infusion of MB-CART2019.1 cells (experimental arm) or the start of SoC therapy (comparator arm) will be approximately 55 weeks. The LTFU in Year 2 after infusion of MB-CART2019.1 cells or the start of treatment in the comparator arm will not be part of the active part of the clinical study and will be reported separately.
In Part II, the study should evaluate the efficacy of MB-CART2019.1 in younger, fit participants with R-R DLBCL. Approximately 45 participants will be enrolled in this part to obtain 40 evaluable participants for the analysis of the primary endpoint.
Screening will take place within 4 weeks before leukapheresis. In individual cases, the sponsor may agree to extending the screening period by up to two weeks. Only participants satisfying all protocol inclusion and none of the exclusion criteria will be included in the clinical study.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- Recruitment completed in Part I: unblinded 1:1 randomization into IMP or SoC (168 patients) Recruitment ongoing in Part II: unblinded, single arm, non-randomized, IMP only (approx. 45 patients)
| Arm | Type | Receives |
|---|---|---|
| Part I: CAR T-cell MB-CART2019.1 | Experimental | Genetic: MB-CART2019.1Single infusion of 2.5 × 10^6 CAR-transduced autologous T cells per kg/body weight. |
| Part II: CAR T-cell MB-CART2019.1 | Experimental | Genetic: MB-CART2019.1Single infusion of 2.5 × 10^6 CAR-transduced autologous T cells per kg/body weight. |
| PART I: Standard of Care | Active comparator | Drug: Standard of CareR-GemOx R-Pola |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MB-CART2019.1Also: Zamtocabtagene Autoleucel, Zamto-celMB-CART2019.1 is designed to effectively target malignant B cells in patients suffering from late stage haematological B-cell malignancies. MB-CART2019.1 consists of autologous cluster of differentiation CD20/CD19 chimeric antigen receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis and processed by using the CliniMACS Prodigy® device. | Genetic | Part I: CAR T-cell MB-CART2019.1, Part II: CAR T-cell MB-CART2019.1 |
| Standard of CareAlso: Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, RituximabStandard of Care | Drug | PART I: Standard of Care |
Primary outcome
Part I: Event-free survival
Time frame: up to 30 weeks after randomisation
Event-free survival (EFS), defined as the time between the date of randomisation and the date of objective disease progression, failure to achieve partial response (PR) or complete response (CR) at or beyond Week 8 after randomisation leading to a new anti-lymphoma therapy or death of any cause, whichever occurs first, based on independent review committee (IRC) assessment.
Part II: Best objective response rate
Time frame: up to 30 weeks after administration of MB-CART2019.1
Best objective response rate (BORR), defined as the proportion of participants with at least one CR or PR between the date of MB-CART2019.1 infusion and the date of objective disease progression, the start of new anti-lymphoma therapy or the date of death from any cause, whichever occurs first, based on IRC assessment.
9 secondary outcomes
Part I: Progression-free survival (PFS)
Time frame: up to 99 weeks after randomisation
Part I: Best complete response rate
Time frame: up to 99 weeks after randomisation
Part I: Duration of complete response
Time frame: up to 91 weeks
Part I: Overall Survival
Time frame: up to 99 weeks after randomisation
Part II: Duration of Response (DOR)
Time frame: up to 91 weeks
Part II: Progression-free survival (PFS)
Time frame: up to 99 weeks after leukapheresis
Part II: Overall Survival (OS)
Time frame: up to 99 weeks after leukapheresis
Part II: Best Complete Response Rate (BCRR)
Time frame: up to 99 weeks after leukapheresis
Part II: Duration of Complete Response (DOCR)
Time frame: up to 91 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jun 2026.
- Derived from this study: PubMed 42933440Borchmann P, van Meerten T, Iacoboni G, Bories P, Dreger P, Mutsaers P, Gopcsa L, Edinger M, Gergely L, von Tresckow B, Neumeister P, Steiner N, Jager U, Moreno AT, Griskevicius L, Lemonnier F, van Doesum J, Kersten MJ, Rudzki JD, Shah NN, Orentas R, Friedrichs B, Miltenyi S, Overstijns T, Burger I, Zadoyan G, Brillant C, Paul P, van Heteren P, Holtkamp S, Vandenberghe P. Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study. Lancet Oncol. 2026 Nov;27(11):1403-1419. doi: 10.1016/S1470-2045(26)00290-1.
- Individual participant dataSharing planned: No
Related trials for Diffuse Large B-cell Lymphoma
Active, not recruitingPhase 1/2
Study of Oral MRT-2359 in Selected Cancer Patients
NSCLC, SCLC
Active, not recruitingEarly Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
B-ALL, DLBCL
Not yet recruitingPhase 2
The CARDIOPROTECT Trial
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity
Not yet recruitingPhase 2
QLS4131 Plus Isa-V-CHOP in Newly Diagnosed, HIV-Negative PBL: A Single-Center, Single-Arm, Phase II Study
Plasmablastic Lymphoma
RecruitingPhase 2
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Peter Borchmann, Prof. Dr. principal investigator
University Hospital of Cologne
51 sites in 14 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing MB-CART2019.1 in people with Diffuse Large B-cell Lymphoma, run by Miltenyi Biomedicine GmbH at 51 sites in 14 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 51 sites in Germany, France, Spain, Austria, Netherlands and 9 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mark Hess, Dr. (+49 160 9897 0124, mark.hess@miltenyi.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Part I: Event-free survival (time frame: up to 30 weeks after randomisation). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04844866, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2026.